Drug Trial Radar · NCT04581512
Study to Evaluate the Safety and Tolerability of EP0042
Last checked: Nov 19, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
70
Planned (sponsor's estimate)
Start
Nov 2, 2020
Primary completion
Dec 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Ellipses PharmaIndustry
- Sponsor type
- Industry
- First posted
- Oct 9, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A research study looking at a new treatment for patients with advanced cancer, to investigate different doses of the experimental study drug, EP0042, in order to determine a dose, which is safe, well-tolerated and likely to be effective in treating AML (acute myeloid leukaemia).
Conditions
- Acute Myeloid Leukemia
- Chronic Myelomonocytic Leukemia
- Myelodysplastic Syndromes
Interventions
EP0042Drug
EP0042 Oral 20 mg 50 mg capsules
VenetoclaxDrug
Venetoclax
Azacitidine (AZA)Drug
Azacitidine
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose-limiting toxicities (DLTs) from the first dose through the end of the DLT observation period.Time frame: First cycle of treatment (28 Days)
Locations
6 sites in 3 countries. Site status is shown where the registry gives one.
Royal Perth Hospital
Perth, Western Australia, Australia · Recruiting
Amsterdam UMC
Amsterdam, Netherlands · Recruiting
Erasmus MC
Rotterdam, Netherlands · Recruiting
University College London Hospital
London, United Kingdom · Recruiting
The Christie Hospital
Manchester, United Kingdom · Recruiting
The Royal Marsden
London, UK, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.